| Patents for A61P 11 - Drugs for disorders of the respiratory system (87,767) |
|---|
| 01/09/2002 | EP1169025A2 Transdermal drug delivery devices comprising a polyurethane drug reservoir |
| 01/09/2002 | EP1168919A2 Low adenosine anti-sense oligonucleotide, compositions, kit and method for treatment of airway disorders associated with bronchoconstriction, lung inflammation, allergy(ies) and surfactant depletion |
| 01/09/2002 | EP0727978B1 Topical aromatic releasing compositions |
| 01/09/2002 | EP0607439B1 Nitrogenous heterocyclic compound |
| 01/09/2002 | CN1330664A Platelet-derived growth factor C, DNA coding therefor and uses thereof |
| 01/09/2002 | CN1330661A Procollagen C-proteinase inhibitors |
| 01/09/2002 | CN1330655A Fused 1,2,4-thiadiazine derivatives, their preparation and use |
| 01/09/2002 | CN1330643A IL-5 inhibiting azauracil pyrimidine derivatives |
| 01/09/2002 | CN1330640A Cyclic hydrazine derivatives as TNF-alpha inhibitors |
| 01/09/2002 | CN1330637A Compounds useful in treatment of infammatory diseases |
| 01/09/2002 | CN1330631A Amide derivatives which are useful as cell factor inhibitors |
| 01/09/2002 | CN1330555A Antibodies to truncated VEGF-D and uses thereof |
| 01/09/2002 | CN1329905A Concentrated granular medicine for treating baby's cough and asthma and its preparing process |
| 01/09/2002 | CN1329890A Dual-layer slow releasing tablet of benproperine phosphate |
| 01/09/2002 | CN1077573C Heterocycles useful as neurokinin antagonists |
| 01/08/2002 | US6337408 Compounds and method for preparing substituted 4-phenyl-4-cyanocyclohexanoic acids |
| 01/08/2002 | US6337325 Combined preparation for the therapy of immune diseases |
| 01/08/2002 | US6337069 Method of treating rhinitis or sinusitis by intranasally administering a peptidase |
| 01/08/2002 | CA2159915C Systemic effects of nitric oxide inhalation |
| 01/03/2002 | WO2002000892A1 Triple fusion proteins comprising ubiquitin fused between thioredoxin and a polypeptide of interest |
| 01/03/2002 | WO2002000887A1 Novel therapeutic molecular variants and uses thereof |
| 01/03/2002 | WO2002000860A2 Novel proteases |
| 01/03/2002 | WO2002000730A2 Pd-l2 molecules: novel pd-1 ligands and uses therefor |
| 01/03/2002 | WO2002000727A2 Gp286 nucleic acids and polypeptides |
| 01/03/2002 | WO2002000710A2 B7-like molecules and uses thereof |
| 01/03/2002 | WO2002000692A2 Pd-l2 molecules: pd-1 ligands and uses therefor |
| 01/03/2002 | WO2002000691A2 Polynucleotides and polypeptides encoded thereby |
| 01/03/2002 | WO2002000679A2 9.alpha.-chloro-6.alpha.-fluoro-17.alpha.-hydroxy-16-methyl-17-beta-methoxycarbonyl-androst-1,4-dienes esterified in position 17.alpha. by a cyclic acyl group |
| 01/03/2002 | WO2002000676A1 Purine derivatives |
| 01/03/2002 | WO2002000661A1 PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS AS IMMUNOSUPPRESSIVE AGENTS |
| 01/03/2002 | WO2002000658A1 Cyclic gmp-specific phosphodiesterase inhibitors |
| 01/03/2002 | WO2002000656A2 Pirazino '1$m(1)2$m(1) :1, 6! pyrido '3,4-b! indole derivatives |
| 01/03/2002 | WO2002000652A1 Carbamates derived from arylalkylamines |
| 01/03/2002 | WO2002000631A2 Benzhydryl derivatives |
| 01/03/2002 | WO2002000609A2 2,6,7-substituted tetralines useful for the preparation of medicaments with phosphodiesterase iv inhibitory activity |
| 01/03/2002 | WO2002000593A2 Compounds useful for the preparation of medicaments with phosphodiesterase iv inhibitory activity |
| 01/03/2002 | WO2002000218A2 Methods of treating neutrophil-related diseases with topical anesthetics |
| 01/03/2002 | WO2002000217A1 Use of 3-substituted oxindole derivatives as kcnq potassium channel modulators |
| 01/03/2002 | WO2002000200A1 Novel process for preparing crystalline particles |
| 01/03/2002 | WO2002000197A1 Method of making particles for use in a pharmaceutical composition |
| 01/03/2002 | WO2002000172A2 Methods for using tetanus toxin for benificial purposes in animals (mammals) |
| 01/03/2002 | WO2002000167A2 Modified forms of pharmacologically active agents and uses therefor |
| 01/03/2002 | WO2002000017A2 Erk-5 deficient animals and methods of inhibiting angiogenesis through the inhibition of erk-5 |
| 01/03/2002 | WO2001072669A3 Therapeutic use of polyhydroxy amine derivates |
| 01/03/2002 | WO2001066544A3 Tricyclic dihydropyrazolone and tricyclic dihydroisoxazolone potassium channel openers |
| 01/03/2002 | WO2001062233A3 Adenosine receptor modulators |
| 01/03/2002 | WO2001055336A3 Methods and materials relating to cd84-like polypeptides and polynucleotides |
| 01/03/2002 | WO2001045726A3 The use of procyanidins in the modulation of cytokine gene expression and protein secretion |
| 01/03/2002 | WO2001045689A3 Indolinone derivatives for modulation of c-kit tyrosine protein kinase |
| 01/03/2002 | WO2001045676A3 Extended release oral dosage composition |
| 01/03/2002 | WO2001043734A3 Transdermal administration of phenylpropanolamine |
| 01/03/2002 | WO2001032877A3 CpG RECEPTOR (CpG-R) AND METHODS RELATING THERETO |
| 01/03/2002 | US20020002191 Fluoroalkoxy-substituted benzamide dichloropyridinyl N-oxide PDE4 inhibitor |
| 01/03/2002 | CA2414389A1 Methods of treating neutrophil-related diseases with topical anesthetics |
| 01/03/2002 | CA2414210A1 Novel therapeutic molecular variants and uses thereof |
| 01/03/2002 | CA2414150A1 Modified forms of nonsteroidal anti-inflammatory drugs and uses thereof |
| 01/03/2002 | CA2413683A1 Fused cyclic compounds as modulators of nuclear hormone receptor function |
| 01/03/2002 | CA2413547A1 B7-like molecules and uses thereof |
| 01/03/2002 | CA2413301A1 Methods for using tetanus toxin for benificial purposes in animals (mammals) |
| 01/03/2002 | CA2412635A1 Novel proteases |
| 01/03/2002 | CA2412610A1 Gp286 nucleic acids and polypeptides |
| 01/03/2002 | CA2412256A1 Polynucleotides and polypeptides encoded thereby |
| 01/03/2002 | CA2412084A1 Triple fusion proteins comprising ubiquitin fused between thioredoxin and a polypeptide of interest |
| 01/03/2002 | CA2411162A1 Compounds useful for the preparation of medicaments with phosphodiesterase iv inhibitory activity |
| 01/02/2002 | EP1167526A1 IgE-dependent histamine-releasing factor(HRF)receptor, HRF-binding peptides and nucleic acids encoding the same, and uses thereof |
| 01/02/2002 | EP1167363A2 Novel crystalline forms of (3S-trans)-2-(3,4-dihydro-4-hydroxy-3-(phenylmethyl)-2H-1-benzopyran-7-yl)-4-(trifluoromethyl)-benzoic acid |
| 01/02/2002 | EP1167360A1 Human chymase inhibitors |
| 01/02/2002 | EP1167357A1 Alpha-substituted carboxylic acid derivatives |
| 01/02/2002 | EP1166811A2 Metered dose inhaler for fluticasone propionate |
| 01/02/2002 | EP1166794A2 Method of treating retained pulmonary secretions |
| 01/02/2002 | EP1165827A1 45 human secreted proteins |
| 01/02/2002 | EP1165795A2 Streptococcus pneumoniae antigens |
| 01/02/2002 | EP1165790A1 Protease activated receptor 2 variants |
| 01/02/2002 | EP1165789A2 Vesicle associated proteins |
| 01/02/2002 | EP1165788A2 Molecules of the immune system |
| 01/02/2002 | EP1165784A2 Nucleic acids including open reading frames encoding polypeptides; "orfx" |
| 01/02/2002 | EP1165781A2 Protease resistant flint analogs |
| 01/02/2002 | EP1165780A2 Flint polypeptide analogs |
| 01/02/2002 | EP1165777A2 Genes encoding human potassium channel proteins |
| 01/02/2002 | EP1165606A1 50 human secreted proteins |
| 01/02/2002 | EP1165566A1 Pyridine and pyrimidine derivatives and their use as inhibitors of cytokine mediated disease |
| 01/02/2002 | EP1165562A1 Cyclic substituted fused pyrrolocarbazoles and isoindolones |
| 01/02/2002 | EP1165558A1 Derivatives of pyrimido[6,1-a]isoquinolin-4-one |
| 01/02/2002 | EP1165556A1 Derivatives of pyrimido[6,1-a]isoquinolin-4-one |
| 01/02/2002 | EP1165555A2 Aryl fused 2,4-disubstituted pyridines: nk3 receptor ligands |
| 01/02/2002 | EP1165554A1 New endothelin converting enzyme inhibitors, their production and their use |
| 01/02/2002 | EP1165545A1 Novel compounds |
| 01/02/2002 | EP1165544A1 Substituted 1,4-dihydroindeno[1,2-c]pyrazoles as inhibitors of tyrosine kinase |
| 01/02/2002 | EP1165533A2 Compounds and methods for treatment of asthma, allergy and inflammatory disorders |
| 01/02/2002 | EP1165528A1 Novel morpholine derivatives, method for the production thereof and pharmaceutical preparations containing said derivatives |
| 01/02/2002 | EP1165518A2 Benzimidazole and imidazolopyridine derivatives, their preparation and their use as selective modulators of bradykinin b2 (= bk-2) receptors |
| 01/02/2002 | EP1165516A2 Heterocyclic urea and related compounds useful as anti-inflammatory agents |
| 01/02/2002 | EP1165514A1 3-(anilinomethylene) oxindoles as protein tyrosine kinase and protein serine/threonine kinase inhibitors |
| 01/02/2002 | EP1165143A2 Method for expressing proteins |
| 01/02/2002 | EP1165115A1 Modulation of vascular permeability by mean of tie2 receptor activators |
| 01/02/2002 | EP1165114A1 Use of a lectin or conjugates for modulation of c-fibre activity |
| 01/02/2002 | EP1165072A2 Valdecoxib compositions |
| 01/02/2002 | EP1165059A1 Pharmaceutical compositions comprising troponin subunits, fragments and homologs thereof and methods of their use to inhibit angiogenesis |
| 01/02/2002 | EP1165043A1 Drinkable pharmaceutical solution |
| 01/02/2002 | EP1164846A1 Prostaglandin compounds, compositions and methods of treating peripheral vascular disease and pulmonary hypertension |